PART I . Forward-Looking Statements This Annual Report contains forward-looking statements within the meaning of Section27A of the Securities Act and Section21E of the Exchange Act that are based on our managements beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to: our ability to successfully commercialize ANKTIVA globally in NMIBC, NSCLC or other indications or any future approved products in the U.S. or ...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-23 | 2025-12-31 | 0001326110-26-000030 | EDGAR | 153K words |
| 2025-03-03 | 2024-12-31 | 0001326110-25-000033 | EDGAR | — |
| 2024-03-19 | 2023-12-31 | 0001326110-24-000037 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001326110-23-000018 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001326110-22-000011 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010945 | EDGAR | — |
| 2020-03-25 | 2019-12-31 | 0001564590-20-012816 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001564590-19-007562 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005290 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001564590-17-004430 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001326110-25-000139 | EDGAR | 110K words |
| 2025-08-05 | 2025-06-30 | 0001326110-25-000114 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001326110-25-000071 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001326110-24-000111 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0001326110-24-000103 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001326110-24-000064 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001326110-23-000147 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001326110-23-000098 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001326110-23-000064 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001326110-22-000074 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001326110-22-000058 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001326110-22-000027 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-06 | 0001193125-26-142932 | EDGAR | 1K words |
| 2026-03-31 | 0001193125-26-133363 | EDGAR | — |
| 2026-02-23 | 0001326110-26-000025 | EDGAR | — |
| 2026-02-18 | 0001326110-26-000018 | EDGAR | — |
| 2026-01-26 | 0001326110-26-000014 | EDGAR | — |
| 2026-01-15 | 0001326110-26-000008 | EDGAR | — |
| 2026-01-14 | 0001326110-26-000004 | EDGAR | — |
| 2025-12-29 | 0001193125-25-331244 | EDGAR | — |
| 2025-12-15 | 0001326110-25-000146 | EDGAR | — |
| 2025-12-12 | 0001326110-25-000143 | EDGAR | — |
172 total filings indexed. 140 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001326110 |
| Ticker | IBRX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.immunitybio.com |
| Listed | 2021-03-10 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report